FinVector Oy and the City of Kuopio have signed an agreement under which FinVector acquires two plots of land located in the Savilahti area. One is where the company’s new gene therapy manufacturing site, Finport, is being built, and the other is the adjacent plot neighbouring the site. The total value of the acquisition is slightly under 3.9 million EUR and the total area of the plots is almost 1.6 hectares.
“The acquisition is an investment for the future, aiming to secure FinVector’s potential growth and expansion possibilities. This is a strong commitment to the long-term development of activities in Kuopio. We would like to thank the City of Kuopio for their continuous support and a smooth purchase process”, says Matthias Krieger, Managing Director, FinVector Oy.
FinVector’s Managing Director, Matthias Krieger (on the left), received the city pennant of Kuopio from the Mayor of Kuopio, Soile Lahti (on the right).
At the same time, the building of the new state-of-the-art manufacturing unit Finport is closing to its end. The building process has proceeded according to schedule. The contractor Rakennusliike U. Lipsanen Oy will hand in the keys to the facility at the beginning of April, after which the furnishing of the offices starts.
“The construction has proceeded according to plan and the site is starting to be ready for the handover. The cleanroom area is already undergoing numerous qualification processes. The general areas start to look like an actual office. For the other, smaller plot we have no concrete plans yet”, says Tony Lönnbäck, Capital Project Director, FinVector Oy.
The new production unit is expected to fully start operations in 2025 including manufacturing technology (cleanrooms). Production on a larger scale is expected to be started in two years, depending on required approvals from authorities.
For more information, please contact:
Aku Kukkola
Communication Specialist
media@finvector.com